Investigators analysed community-based electronic health records from the CRADLE database spanning 66 Irish general practices to describe chronic kidney disease in primary care. The cohort included 468,534 adults active on 30 July 2025; among them 19,382 met laboratory criteria for CKD, producing an age- and sex-standardised prevalence of 5.36%. The study team reported raw counts and standardised prevalence only; details such as stage distribution or eGFR thresholds used for CKD staging were not reported in the source.
This prevalence figure anchors the scale of kidney disease seen in routine Irish primary care. It also frames the subsequent assessment of monitoring and medication patterns, because the authors used these laboratory-confirmed cases as the denominator for follow-up testing and treatment analyses.
Data indicated follow-up kidney function testing increased over time after a laboratory-confirmed CKD result. Within 12 months, 66.0% of patients received a repeat eGFR test. That proportion shows some attention to renal function monitoring in primary care. However, the study team observed much lower uptake for albuminuria testing: only 15.1% of laboratory-confirmed CKD patients had a uACR test within 12 months. The gap widened among patients without type 2 diabetes, where uACR testing fell to 6.6%.
The authors emphasised the discrepancy between creatinine-based surveillance and albuminuria measurement. The source did not provide specific reasons for low uACR uptake, nor did it report whether point-of-care or laboratory barriers were assessed. Those details were not included in the manuscript.
Among patients deemed eligible for guideline-directed medical therapy (GDMT), 64.0% received any renin–angiotensin–aldosterone system inhibitor (RAASi) after meeting prescription eligibility criteria documented in the records. A lower proportion—30.9%—received any sodium–glucose cotransporter 2 inhibitor (SGLT2i) following eligibility. Uptake of SGLT2i dropped to 9.4% among patients without T2DM or heart failure, indicating a marked disparity in prescribing patterns across clinical subgroups.
The authors presented these prescription rates as descriptive outcomes from routine prescribing data. They did not report granular timing relative to guideline publication, nor did the source include adjusted analyses to explore drivers of non-prescription (such as contraindications, patient refusal, or specialist input). Those specifics were not available from the preprint text.
Cardiometabolic disease was highly prevalent in the CKD cohort. The study team reported that 74.0% of laboratory-confirmed CKD patients had at least one cardiometabolic comorbidity. The manuscript did not break down the exact distribution of individual comorbid conditions within that 74.0% in the text provided, although the authors noted the burden shapes risk and treatment needs in primary care.
High comorbidity prevalence matters for both monitoring and pharmacotherapy decisions. It likely influenced the higher SGLT2i uptake among patients with T2DM or heart failure compared with those without those conditions, as described by the investigators.
The investigators declared ethical approval from the Irish College of General Practitioners Research Ethics Committee (Reference: 2682). They also stated that the datasets analysed are not publicly available; access may be granted by the corresponding author subject to data custodian permissions and governance processes. Three authors reported employment with Boehringer Ingelheim; the remaining authors declared no competing interests.
The authors reported descriptive findings but did not provide some methodological details in the publicly posted preprint. For example, the source did not report CKD staging breakdowns, the specific eGFR thresholds used for cohort inclusion beyond laboratory confirmation, nor granular reasons for non-prescription of GDMT. The study design was retrospective and reliant on routine EHR data, which can introduce incompleteness in testing or prescribing records; the source notes these inherent limits to interpretation. Access constraints for the dataset mean independent external validation requires governance approval and direct contact with the corresponding author.
Remaining clinical questions the authors left open include why uACR testing remains low in non-diabetic patients and what system-level interventions in Irish primary care would most effectively increase timely uACR measurement and GDMT initiation. The preprint did not specify planned regulatory milestones or prospective interventions; those were not reported in the source.